Nav: Home

Cancer researchers look at resistance to targeted therapy in mantle cell lymphoma

June 14, 2017

WASHINGTON (June 14, 2017) -- Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called Ibrutinib, forgoing conventional chemotherapy. However, many are developing a resistance to this treatment. Research published in Nature Communications by Eduardo Sotomayor, MD, director of the George Washington University Cancer Center and Jianguo Tao, MD, PhD, senior member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, details how lymphoma cells are acquiring their resistance.

"Not all patients will react to a drug in the same way," said Sotomayor. "Some will take it and no longer show symptoms of lymphoma. In others, they may not show a response to the treatment at all, and in other, after an initial response to treatment, the lymphoma may come back more aggressive than before. What we wanted to understand is: How can we make this treatment work for everyone?"

In the past, those diagnosed with mantle cell lymphoma received chemotherapy and monoclonal antibody treatments, which often led to a number of side effects. Some patients are now treated with ibrutinib, a daily pill that has been associated with significant positive response by lymphoma patients. Sotomayor and his research team wanted to understand the lymphoma cells and the mechanisms that allow them to develop resistance to the drug.

"As shown in the past by Dr. Tao's group, mantle cell lymphoma cells depend on strong interactions with the microenvironment for progression. Rather than focus on the cells themselves, our team was concerned about understanding the microenvironment where the cells thrive and find protection," Sotomayor explained. "We need to look at the tumor cells in the context of the microenvironment to understand how they build up resistance."

The team noticed that when ibrutinib shut down the bruton tyrosine kinase pathway that the lymphoma cells thrived in, the cells adapted and began to activate another pathway, noted in the study as PI3K-AKT-mTOR. This allowed the cancer cells to come back, in some cases as more aggressive. Not only did the cells adapt to the drug, they adapted to its effects on the space around them and adapted the microenvironment facilitating further progression. Exploring methods for inhibiting the pathways and resistance networks would be a next step in finding a way to make ibrutinib an even better drug for more patients.
The study titled, "Unification of de novo and Acquired Ibrutinib Resistance in Mantle Cell Lymphoma" was published in Nature Communications at

Media: To interview Dr. Sotomayor, contact Ashley Rizzardo at or 202-994-8679

About the GW Cancer Center

The George Washington University (GW) Cancer Center is a collaboration between the GW Hospital, the GW Medical Faculty Associates, the GW School of Medicine and Health Sciences, and the Milken Institute School of Public Health at GW to expand GW's efforts in the fight against cancer. The GW Cancer Center also incorporates all existing cancer-related activities at GW, serving as a platform for future cancer services and research development. Learn more about the GW Cancer Center at

George Washington University

Related Lymphoma Articles:

Lymphoma stage at diagnosis may predict when and where new cancer forms
Colorado study shows the stage at which lymphoma is originally diagnosed impacts the types of second cancers that may form after treatment.
New factor in the development of childhood lymphoma
The immune system is highly complex and a detailed understanding of many underlying mechanisms is still lacking.
CNIO discovers a connection between nutrients and follicular lymphoma
CNIO researchers have identified the role played by mTOR pathway as the origin of follicular lymphoma and propose the exploration in future studies of a possible therapeutic strategy using a drug that is already being used in clinical practice to treat other tumors.
Antibiotics can inhibit skin lymphoma
New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma.
Association of BRCA2 mutations with risk of childhood lymphoma
This research letter reports on the association of BRCA2 gene mutations and potential risk for pediatric or adolescent lymphoma.
Why Hodgkin's lymphoma cells grow uncontrollably
Although classical Hodgkin's lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery.
New tool to find and fight most dangerous types of lymphoma
UK scientists have found a new way to identify people with the most aggressive types of lymphoma who are less likely to respond to standard drugs.
JAK inhibitors associated with aggressive lymphoma
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.
New epigenetic drug against Mantle Cell Lymphoma
A new study by doctor Manel Esteller's group at IDIBELL presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL).
Attacking lymphoma at the source
The efficacy of target specific therapies in lymphoma is limited to subgroups of patients.
More Lymphoma News and Lymphoma Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at